Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada

Toronto, Canada (ots/PRNewswire) - Archimed, the woundcare
division of Insense Ltd., today announced it has received approval
from Health Canada for the use of its revolutionary Oxyzyme product
in the treatment of difficult and chronic wounds. Oxyzyme was first
trialed in Toronto by Dr. Gary Sibbald, one of the world's leading
wound care specialists, in 2004 by his team at the Toronto Wound
Healing Centres. The announcement was made at the 3rd Congress of the
World Union of Wound Healing Societies taking place from June 4-8,
2008 at the Metro Toronto Convention Center.

Oxyzyme is a biochemical system in a dressing that ensures the
oxygen in the wound environment meets the diverse oxygen needs of
the cells responsible for healing. Ongoing clinical programs being
undertaken in Europe are showing that 20% of old, previously
unhealable wounds (3.5 years ) are now closing in six weeks or under
when dressed with Oxyzyme. Easy to use by any clinical professional,
Oxyzyme will now soon be available to the Canadian health care
system at a modest cost.

In conjunction with the announcement, Professor T.K. Hunt, often
cited as the father of modern wound care, was awarded a lifetime
achievement award by the World Union of Wound Healing Societies.
Professor Hunt's insight and discoveries on the role oxygen plays in
the healing process was the inspiration behind the development of
Oxyzyme.

"The real value of Oxyzyme is that it combines two agents -
iodine and oxygen - that are essential to the process of wound
healing and provides further opportunities to overcome barriers to
healing that may exist in the patient," explained Dr. Keith Harding,
leading figure in the international wound care community and also a
member of the World Union faculty.

For more information about Oxyzyme and Archimed visit
http://www.archimed.co.uk.

About Insense Ltd.

------------------

Insense is a British biotechnology company founded by Professor
Paul Davis, Chief Scientific Officer, who led the team which
invented and developed the ClearBlue(TM) pregnancy test. The company
is also developing products out of its core technology for
dermatology and health and beauty applications. For more information
about Insense Ltd. visit www.insense.co.uk.

For further information: Professor Paul Davis, Chief Scientific
Officer , Founder, and Inventor, Paul.davis@insense.co.uk,
+44-7825-983-216/

ots Originaltext: Insense Ltd.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Professor Paul Davis, Chief Scientific
Officer, Founder, and Inventor, Paul.davis@insense.co.uk,
+44-7825-983-216/